Biogen, AbbVie and Regeneron set to gain from tax reform: analyst

Fierce Pharma -------- With the New Year comes a new tax system in the U.S., and now many analysts and consultants are digging into how the GOP's reform will affect major pharma players. This week, Leerink Partners analysts are out with their picks for the large biotechs that will see the most benefit, and a few that might pay more. In a note Thursday, Leerink analyst Geoffrey Porges wrote that of companies in his team's coverage, Biogen, AbbVie and Regeneron are set to gain the most from the tax bill. Biogen and AbbVie currently have "relatively suboptimal tax structures," he wrote, and will likely make up ground from the changes. To learn more click on the picture below to read the article.